Sanofi/Regeneron Ready To Forge Ahead With Libtayo Filings In NSCLC
Executive Summary
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.
You may also be interested in...
Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Regeneron Maintains Its Momentum During Pandemic
The company reported strong 33% revenue growth in Q1, despite softer Eylea sales from postponed treatments, progressed in oncology, and is moving an antibody cocktail for COVID-19 into clinical testing.
Sanofi/Regeneron Ready To Forge Ahead With Libtayo Filings In NSCLC
Cemiplimab was a latecomer to the PD-1/L1 class, but a Phase III success in lung cancer will bring it to the main stage for immuno-oncology.